Değer202020212022202320242025TTMSatış/genel/idari giderler6.71 M21.23 M32.55 M33.3 M26.09 M16.68 M18.32 MAraştırma ve geliştirme13.29 M42.79 M61.46 M93.79 M70.68 M17.5 M24.46 MFaaliyet karı-20 M-64.02 M-104.02 M-125.47 M-100.9 M-102.27 M-109.94 MFaaliyet Dışı Gelir, Toplam-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.43 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)367 K3 000—————Faaliyet Dışı Gelir (Faiz Giderleri Hariç)-367 K-3 00000000Olağandışı gelirler/giderler-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.43 MVergi öncesi kar-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-135.81 MKazançlardaki özsermayeler———————Vergiler-4.3 M-13.5 M-20.4 M-28.3 M-20.7 M0—Kontrol gücü olmayan/azınlık payı———————Vergi sonrası diğer gelirler/giderler———————Durdurulan faaliyetler öncesi net kar-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MDurdurulan faaliyetler———————Net kar-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MSeyreltme ayarlaması———————İmtiyazlı temettüler———————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MTemel hisse başına kazanç (Temel EPS)——-25.3-30.9-25.2-24.7-24.09Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)——-25.3-30.9-25.2-24.7-24.09Dolaşımdaki ortalama adi hisse senedi sayısı——3.77 M3.8 M3.85 M4.28 M—Dolaşımdaki seyreltilmiş hisse senedi sayısı——3.77 M3.8 M3.85 M4.28 M—FAVÖK-19.54 M———-100.44 M——FVÖK-19.8 M———-100.91 M——Gelir maliyeti———————Satılan malların diğer maliyeti———————Amortisman ve itfa (nakit akışı)253 K972 K423 K-445 K455 K643 K436 K
LeonaBio, Inc. - Common Stock
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.